Member Info for oogleflugal

Priceless. Pretty much the argument Iain Macleod used in his short term as health minister for A Tory government. ‘We couldnt afford the loss of tax revenue from banning smoking’, just before he died from a fatal heart attack at the age of 57.

The really sad thing is that investigations of a link between lung cancer and smoking were initiated back in 1954. It was also suggested at that time that young people should be warned of the harmful effect of smoking.

The argument that a culling of the population by letting them continue smoking would deprive them of becoming ill from another illness later in life is an interesting one. The reality is that the cost to the NHS from respiratory illness and other diseases related to smoking far outweigh any other cost to the NHS. Apart from that the ideas and pr put into smoking by the tobacco industry is gross. The lies, cover ups and intimidation to protect their enormous wealth and power are obscene.

Part apart from that who doenst enjoy the occasional ciggie

Helllo , anyone out there? Avg not actually involved with the bit of Hs2 that is being cancelled.

Barchid. I agree Mrch have done pretty well over years . Not sure how it measures against inflation with so little capital growth. It’s the companies they invest in I dislike. 700 point drop in Nikkei. Hangseng also down 2.5 percent. Shanghai and FTSE are the stars going nowhere. Lot of fixed interest rates over 5 per cent now . Apparently pension fund stock investment are lowest levels in years. Should mean a strong bounce. Maybe not this year. What I find strange about the Bg (which included mnks and smt) strategy about investing in unlisted stock is how poorly they have performed compare to iii.

Monster over reaction. Strong balance sheet, cash in bank. Has been a bit of a mini global crash everywhere except the cause, China. Naked T warned about catching a falling knife. He did at £1.37. Wonder if his stop kicked in. Never did trust those things. Takes you out on a spike or market maker fishing expedition. Lets hope this is temporary in which case with 200 million in the bank they are a lot better positioned than many. Gl

Slight note of caution is the PE is quite high for sector. Stockopedia says 16 which is not too bad others have it mid twenties and dear old LSE comes in with a completely doolalley 60. Not their strong point financial data. They are expensive as are most good shares with value and growth. They look well set for the long term, but clearly the market is cautious. Gl

As expected resolution passed for capital reduction and proposal of 1.5p maiden dividend. Court approval sought by end of month.

Having top sliced , bottom sliced and middle sliced last week, frantically bought them back yesterday and today. Very fortunate with the huge sale bringing the sp right back. They all got gobbled up pretty quick apparently. No idea who or why. I guess the market is always suspicious of anyone doing this well in this climate.General consensus is anywhere between £1.60 and £1.80 would be justified , but they are talking about doubling market size at the same time as increasing margins! Seems incredible with the competition but they are considered the bees knees for service. Not often you can say that about this sector. Gl all

Agreed, a fair presentation. Before anyone panics, Nigel’s apparent % reduction in his holding is because the placing adding extra shares to the share count. I dont actually remember a similar announcement from the 2p placing which would have had the same effect. I do sympathise with long term holders. Many false dawns, but this does look the most promising product so far. It is a slight concern that n4p lipid deal looks a bit too good to be true. It may simply be that the terms were better and fairer to both parties than anyone else was prepared to offer and that n4p are already connected with drug companies prepared to trial their delivery system, plus the research foundation with the university in Queensland. Positive, but still a lingering frustration

If interested Walp posted reply on Mnks by mistake. I wish you all well on here but I wouldnt ever invest in Trusts again

Sure. Just look at mnks just about back pre-pandemic levels. Then the Japan trusts , Bsg and Bgfd have performed abysmally especially compared to the nikkei index which has actually recovered substantially . They have lost between 30 and 50% in 2 years while the nikkei has risen over 20% over the same period. Yes they are not aligned to the nikkei they tell me . Stating the bleeding obvious.They say they have reorganised some of the holdings in those trusts and actually only succeeded in making them worse. I have watched the presentations which are very unprofessional virtually at joke level technically. I have done pretty well with SMT over many years. This cant be the same management team. Would not touch with a barge pole. It really has been an eyeopener. I used to have other trusts Atst, Majedie (possibly even worse than Ballie Gifford, which is quite an achievement in itself) Mrch and Mrc. I am completely finished with trusts and all those other ‘professionally’ managed funds. Trust is the last thing I would do. Part of their problem is that they have too much money to look after. Mrch is probably the best managed . Hasnt really gone anywhere in 25 years but has maintained a pretty good divided throughout, heavily subsidised by some pretty horrible companies. Far too much advertising trying to seduce investors into funds.It is no easy matter investing for yourself, but it would take some talent to perform worse than some of these ‘experts.’

I think Ballie Gifford should undergo a thorough examination to ascertain if they have single competent person to manage any of their trusts. They are an utter disgrace across the board in every sector

Pretty erratic share price movement since results, and there we have it. 950000 order filled late reported from 9 this morning. O what fun games these manipulators have!

To me the RNS explains adequately the difference between what Nuvec is being trialed for and what Nanogenic’s lipids is being trialed for. Very different diseases, for treatment in different organs with special requirements. There are billions of pounds being spent in the USA on nanotechnology all trying to provide similar therapies with different delivery systems to deliver toxic drugs in a safer and less intrusive way. This acquisition has doubled our chances of getting to commerciality in huge markets. Of course it may never happen and N4p may well die trying. The pandemic may have been a bit of a red herring as we have seen many companies collapsing in the aftermath . As we have seen in the news recently Covid is far from dying, and whatever people feel about vaccine they are going to continue to play a big part in our survival. Clearly Nigel is not an idiot. Whether he is successful or not is another matter. There a far more entrepreneurs that fail especially in this industry, but the ones that succeed are worth the weight in gold. That is the nature of this capitalist system for better or worse

Brett Gordon ( 4th largest holder) upped stake .5%

i can see a real synergy combining the two companies. nagogenics expect their product to be in clinic in 2025. not sure what their financial state is but we seem to have financed them to that in clinic stage. the deal allows them to still have enough skin in the company should this go commercial. nigel has always said he was open to an acquisition. this looks the best fit he could have achieved. it also broadens the range of n4p with a ready made almost ready to go product. biotech has suffered all round this year with the big pharmaceuticals cutting back on expenditure. the word is that that is changing for the coming year. this looks like a better investment than money doing nothing, although they raised all the cash to buy this, but the cash they do have should see them through to 2025, as they both appear to have minimal expenditure requirements. a much needed extra string to the bow. forget the sp, this is **** or bust now

Its an outrage Darton. Having to buy own shares whatever next ? A huge increase in revenue would seem apporiate

Not only is it’s principal target a huge market, helping patients recover glaucoma surgery, Nigel sees the potential in Lung and liver disease. Cant accuse him of being short sighted. Might actually top up this time when it goes sub 1p

Actually it does sound bloody amazing, but then so did Nuvec. Thats one thing about N4p its better than doing open university in medical procedures!

Another day another begging bowl. 9.5% is actually quite reasonable for a basket case. Its just the other terms seem to ensure the sp remains suppressed till the next raise in six months or less .

It may be a great buy, but its cost us 50% of the company to do it. Requires an explanation Nige. Rationale not in N4p vocabulary.

Charles Stanley took opportunity to top as did I. O ward and upward